ArticleJournal of molecular and cellular cardiology plus2026
SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure.
Article in Journal of molecular and cellular cardiology plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardioprotective effects in heart failure (HF), yet the molecular mechanisms underlying these benefits remain incompletely understood. This study aimed to characterize cardioprotective effects of SGLT2i, changes of circulating growth and inflammatory factors, as well as adipose tissue gene expression, in subjects with advanced HF (stage D). Methods: 27 subjects with HF undergoing cardiovascular surgery were included, comprising 17 subjects treated with SGLT2i and 10 untreated controls. Soluble factors were analysed using Luminex assay, and mRNA expression in subcutaneous (SAT) and epicardial adipose tissue (EAT) was assessed. Results: Subjects receiving SGLT2i exhibited a non-significant trend toward lower BNP concentrations (329.1 ± 78.7 vs. 514.2 ± 103.8 pmol/L, Conclusions: SGLT2i therapy in advanced HF was associated with higher circulating IL-10, TGF-α and sVEGFR3 levels and with a more favourable adipose tissue gene expression profile characterized by lower expression of genes related to inflammation, fibrosis, and cellular senescence. These findings identify molecular pathways associated with SGLT2i therapy that warrant further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.